On Demand Webinar

Take Your AAV Titers to New Heights

Reach higher yields and efficiency with the turnkey transfection system built specifically to maximize your AAV production

Take Off

On Demand Webinar

Take Your AAV Titers to New Heights

Reach higher yields and efficiency with the turnkey transfection system built specifically to maximize your AAV production

Take Off

Affinia Therapeutics, a leader in AAV technology, has rigorously tested the TransIT®-AAViator Transfection System and the results are clear: significant boosts in titer and percent full capsids, scalability across platforms, and cost reduction potential, all without sacrificing quality.

These results were observed across several testing platforms, from small shake flasks to bioreactors, proving scalability for both upstream process efficiency and downstream purity.

“In an effort to reduce costs, we focus on improving purity. One of the ways around that is by increasing percent-full capsids. The TransIT-AAViator Transfection System has been able to do that for us. “

Michael White, Ph.D.

Head of Process Development and Manufacturing Innovations
Affinia Therapeutics

Key Performance Data

  • 2X Increase in Titer:

    Affinia’s side-by-side comparison shows that using the TransIT-AAViator Transfection System results in a substantial boost in titer compared to the control reagent. The transition from their standard platform doubled titers out of the box in their first experiment.

  • Increase in Percent-Full Capsids:

    With optimized conditions and DNA ratios, the percentage of full capsids increased, impacting downstream purification.

  • Plasmid System Compatibility:

    The TransIT-AAViator Transfection System shows additional versatility with higher titer and percent full capsids than historical benchmarks across different plasmid systems.

  • Significant Cost Reduction:

    Michael highlights the potential to cut total pDNA usage by 50% while further increasing titer to 2e12.

AAViator transfection
Watch the Webinar

A Tour of the Cockpit: TransIT-AAViator Transfection System

Watch the webinar to see how the system flies

  • How the polymer and lipid transfection system was designed for maximum AAV delivery
  • How the Transfection System incorporates RevIT AAV Enhancer for an even greater viral vector yield
  • Straightforward transfection protocol, allowing for seamless integration into existing workflows

Our Jetstream Upstream Pilot

Michael White, Ph.D.

Head of Process Development and Manufacturing Innovations
Affinia Therapeutics

SCALABILITY

The first thing we saw was a substantial increase in titer—moving from 2e11 to 6e11, which was exciting. What caught our attention even more was the increase in percentage of full capsids, going from 25% to nearly 60%.

Michael White

Head of Process Development and Manufacturing Innovations

OPTIMIZATION

You get an enhancement using TransIT-AAViator no matter where you start. If you’re starting higher, you’ll end higher. But even if you start lower, you’ll still see a significant boost.

Michael White

Head of Process Development and Manufacturing Innovations

COST SAVINGS

Being able to knock half the total DNA requirements off and be able to achieve such high titers and percentiles was really something that was significant to us and represents a huge cost savings down the line.

Michael White

Head of Process Development and Manufacturing Innovations

COMPARISON

When we cut the DNA in half, we actually saw a jump in titer to almost 2X what we observe with FectoVIR.

Michael White

Head of Process Development and Manufacturing Innovations

SCALABILITY

The first thing we saw was a substantial increase in titer—moving from 2e11 to 6e11, which was exciting. What caught our attention even more was the increase in percentage of full capsids, going from 25% to nearly 60%.

Michael White

Head of Process Development and Manufacturing Innovations

OPTIMIZATION

You get an enhancement using TransIT-AAViator no matter where you start. If you’re starting higher, you’ll end higher. But even if you start lower, you’ll still see a significant boost.

Michael White

Head of Process Development and Manufacturing Innovations

COST SAVINGS

Being able to knock half the total DNA requirements off and be able to achieve such high titers and percentiles was really something that was significant to us and represents a huge cost savings down the line.

Michael White

Head of Process Development and Manufacturing Innovations

COMPARISON

When we cut the DNA in half, we actually saw a jump in titer to almost 2X what we observe with FectoVIR.

Michael White

Head of Process Development and Manufacturing Innovations

The Data: TransIT-AAViator Transfection System

See how Michael White and Affinia Therapeutics streamlined their AAV manufacturing

Watch the Flight Plan